Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVITM to Treat Sanfilippo Syndrome Type A (MPS II
FDA approval of Ultragenyx's FAYUVITM validates Andelyn's Curator platform for commercial gene therapy manufacturing.
What changed
FDA approval of Ultragenyx's FAYUVITM validates Andelyn's Curator platform for commercial gene therapy manufacturing.
Why it matters
FDA approval of Ultragenyx's FAYUVITM validates Andelyn's Curator platform for commercial gene therapy manufacturing. — impact context not separately stored; see What changed.
← Dashboard
Sep 18, 2026 01:51 PM ET